Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,900 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: AstraZeneca Clear all
Completed Phase 4 Interventional

Acid-Associated Heartburn Symptoms and Dose of Esomeprazole

NCT00206024
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole magnesium (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
26
States / cities
Tucson, Arizona • Anaheim, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 7, 2026, 6:51 PM EDT
Completed No phase listed Observational

Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia

NCT04566653
View directory record Official record
Conditions
Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure
Interventions
Calcium Polystyrene Sulphonate 15g/60 mL water, Lokelma® 5 g/45mL water, Lokelma® 10 g/45 mL water, Veltassa® 8,4 g/80mL water, Sodium Polystyrene Sulphonate 15g/60 mL water
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Temple Terrace, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 7, 2026, 6:51 PM EDT
Completed Phase 1 Interventional Results available

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

NCT02500979
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Pramlintide acetate, Placebo, Lispro insulin U-100, Regular insulin U-100
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Chula Vista, California • Portland, Oregon • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 7, 2026, 6:51 PM EDT
Not listed Phase 4 Interventional

A Pilot Study Involving an Asthma Management Program for Inner-city Early Head Start Children

NCT00624429
View directory record Official record
Conditions
Asthma
Interventions
Budesonide respules
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
12 Months to 36 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 18, 2009 · Synced Oct 7, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

NCT04076579
View directory record Official record
Conditions
Sarcoma, Sarcoma Metastatic
Interventions
Olaparib, Trabectedin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
16 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 7, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy

NCT04249362
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Durvalumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Tucson, Arizona • Tampa, Florida • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 7, 2026, 6:51 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma

NCT01947946
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • Glendale, Arizona • San Jose, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 7, 2026, 6:51 PM EDT
Completed Phase 1 Interventional

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

NCT02228369
View directory record Official record
Conditions
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Interventions
AZD3759, AZD9291
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 7, 2026, 6:51 PM EDT
Terminated No phase listed Observational

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

NCT05592483
View directory record Official record
Conditions
Breast Cancer
Interventions
None (Observational Study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
40
States / cities
Mobile, Alabama • Chandler, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 7, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

NCT03448718
View directory record Official record
Conditions
Metastatic Urothelial Cancer
Interventions
Olaparib
Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 7, 2026, 6:51 PM EDT
Recruiting Phase 4 Interventional

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

NCT07357597
View directory record Official record
Conditions
Stomatitis
Interventions
Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 7, 2026, 6:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects

NCT01171105
View directory record Official record
Conditions
Healthy
Interventions
AZD5213, Placebo to AZD5213
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 7, 2026, 6:51 PM EDT
Not listed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

NCT02130882
View directory record Official record
Conditions
Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions
benralizumab, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 7, 2026, 6:51 PM EDT
Completed No phase listed Observational

ICS/LABA Adherence and COPD Exacerbation

NCT02446041
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Non-Interventional Study
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 7, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

NCT00617669
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, ZD4054, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
25
States / cities
Greenbrae, California • San Diego, California • Norwich, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 7, 2026, 6:51 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

NCT07511205
View directory record Official record
Conditions
Healthy Participants, Obesity
Interventions
AZD1043, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 7, 2026, 6:51 PM EDT
Completed Phase 1 Interventional

AZD1152 in Patients With Advanced Solid Malignancies

NCT00338182
View directory record Official record
Conditions
Tumors
Interventions
AZD1152 part A, AZD1152 part B
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 7, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion

NCT01919723
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor, Eptifibatide
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Birmingham, Alabama • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 7, 2026, 6:51 PM EDT
Active, not recruiting Phase 2 Interventional

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

NCT04397003
View directory record Official record
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Neoantigen DNA vaccine, Durvalumab, TDS-IM v2.0 Device, Peripheral blood draws
Biological · Drug · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 7, 2026, 6:51 PM EDT
Recruiting Phase 3 Interventional

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060
View directory record Official record
Conditions
Heart Failure
Interventions
Baxdrostat and dapagliflozin, Placebo and dapagliflozin
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
11,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
198
States / cities
Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 176 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 7, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)

NCT00297115
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Roflumilast, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
151
States / cities
Bayou La Batre, Alabama • Birmingham, Alabama • Huntsville, Alabama + 131 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 7, 2026, 6:51 PM EDT
Completed Not applicable Interventional

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

NCT00165308
View directory record Official record
Conditions
Hodgkin's Disease, Breast Cancer
Interventions
Tamoxifen
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Oct 7, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01437540
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium Bromide/Formoterol Fumarate, Formoterol Fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
137
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 7, 2026, 6:51 PM EDT
Terminated Phase 2 Interventional Results available

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

NCT00138125
View directory record Official record
Conditions
Breast Cancer
Interventions
Faslodex, Herceptin
Drug · Biological
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Los Angeles, California • Redondo Beach, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 7, 2026, 6:51 PM EDT